Premium
Quipazine exacerbation of a hyperkinetic syndrome: Involvement of brain dopamine and serotonin
Author(s) -
Langlais P. J.,
Gabay S.
Publication year - 1977
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.490030207
Subject(s) - quipazine , methysergide , serotonergic , serotonin , dopaminergic , haloperidol , dopamine , medicine , psychology , endocrinology , pharmacology , receptor
Abstract Quipazine (5–25 mg·kg −1 , s.c.) was given to rats in which a hyperkinetic syndrome had been previously induced by administration of β;,β′‐iminodiproprionitrile (IDPN). Quipazine produced a significant increase in the circling behavior and choreiform head and neck movements, characteristic of the syndrome. This response could be blocked by pretreatment with the serotonin antagonists, SQ10, 631 (25 mg·kg −1 , i.p.) and methysergide (5.0 mg·kg −1 , i.p.), as well as the dopamine receptor antagonist, haloperidol (0.5 mg·kg −1 , i.p.). These observations are discussed with respect to the nature of the involvement of brain serotonergic and dopaminergic systems in quipazine action on these hyperkinetic disturbances.